Showing results (1-10 of 314) with videos related to
Sort By:
Pageof 32
BMJ Open|July 2, 2016
Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014Anthony J Hatswell, Gianluca Baio, Jesse A Berlin, et al.The Lancet. Oncology|September 2, 2006
Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysisKent R Johnson, Clare Ringland, Barrie J Stokes, et al.Medicina (Kaunas, Lithuania)|January 11, 2007
Determination of drug information needs of health care professionals in EstoniaAin Raal, Krista Fischer, Alar IrsSpringerplus|May 14, 2013
Antibiotic prescription preferences in paediatric outpatient setting in Estonia and SwedenJana Lass, Viveca Odlind, Alar Irs, et al.Pharmacoepidemiology and Drug Safety|March 19, 2011
Off label use of prescription medicines in children in outpatient setting in Estonia is commonJana Lass, Alar Irs, Heti Pisarev, et al.The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|December 17, 2008
Biostatistical aspects for the use of evidence based medicine in health technology assessmentNick FreemantleJournal of Clinical Epidemiology|November 3, 2009
Real-world effectiveness of new medicines should be evaluated by appropriately designed clinical trialsNick Freemantle, Thomas StrackPharmacoeconomics|January 31, 2009
The applicability and generalizability of findings from clinical trials for health-policy decisionsNick Freemantle, Franz HesselPharmacoeconomics|July 16, 2003
A role for two-stage pharmacoeconomic appraisal? Is there a role for interim approval of a drug for reimbursement based on modelling studies with subsequent full approval using phase III data?Suzanne Hill, Nick FreemantleTrials|August 12, 2006
Will availability of inhaled human insulin (Exubera) improve management of type 2 diabetes? The design of the Real World trialNick Freemantle, Thomas R Strack, Pageof 32